The emergence of mephedrone together with other artificial cathinones has presented issues for lawmakers and regulatory organizations tasked with controlling the proliferation of new psychoactive substances. The dynamic nature of artificial drug creation, coupled with the ability of chemists to change molecular buildings to evade authorized limits,